Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost Switching Study in Glaucoma/OH with Corneal Disorders
NCT04737928Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of tafluprost in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoints: Intraocular Pressure at 3 months and Fluorescein Staining Score (NEI) at 3 months. Started Apr 2018; status: completed.
02
Drugs
tafluprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04737928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737928.